Ticagrelor paten?

Is ticagrelor still under patent protection, or has it expired?

Ticagrelor (the active ingredient in Brilinta and its generics) is a branded drug that has moved through patent and exclusivity timelines. Exact “still under patent?” status depends on the country because patent coverage and regulatory exclusivities do not line up globally.

Which patents control ticagrelor in the US vs Europe?

Patent status for ticagrelor typically depends on:
- The original composition-of-matter patent term and any extensions
- Product/formulation patents (if any)
- Methods-of-use claims
- Country-specific patent filings and litigation outcomes

If you tell me your country (US, UK, EU, Canada, etc.), I can narrow the answer to the relevant jurisdictions.

When did ticagrelor’s main exclusivity start/end?

Without country-specific data, it’s not possible to give a reliable end date, because “patent expiry” and “regulatory exclusivity” (which can include data exclusivity/market exclusivity) can extend market protection even after some patents end.

Can generics or biosimilars be sold before all patents expire?

Yes. Even when some patents remain in force, generics can sometimes launch if:
- They avoid infringing the remaining claims, or
- A court/litigation process clears the way, or
- There are licensing or non-infringement rulings

So “patent expiry” is not the only factor determining when generic ticagrelor products appear in pharmacies.

What do people usually mean by “ticagrelor patent?” (composition vs brand vs patents on specific products)

Patients and buyers often ask “patent” meaning one of these:
- Branded product protection (market exclusivity)
- Specific drug-ingredient patents (composition of matter)
- Specific formulation strengths (e.g., tablet strengths)
- Specific manufacturing or method patents

Those lead to different answers, so the country and the exact product matter.

What’s the quickest way to check ticagrelor patent status for your needs?

Reply with:
1) Your country (or where you want to buy/use it), and
2) The brand/generic name you care about (e.g., Brilinta 60 mg/90 mg),

and I’ll focus the answer on the most relevant patent/exclusivity questions for that market.

Sources: none provided in the prompt.